Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD2693 in Hepatic Impairment
NCT05919069Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2023
- Primary completion
- Sep 2024
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
Phase 1, open-label trial of AZD2693 in Nonalcoholic steatohepatitis (NASH) (4 arms), sponsored by AstraZeneca. Primary endpoints: Area Under the Plasma Concentration-Time Curve from Time Zero to Infinity at 85 days, Area Under the Plasma Concentration-Time Curve from Time Zero to the Last Quantifiable Concentration at 85 days and 1 more. Started Jun 2023; status: completed.
02
Drugs
AZD2693
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT05919069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05919069.